USPH

SEC source: 0001209191-19-059414 · doc4.xml · nonDerivative · entry 1

Gilmartin Kathleen A · CIK 0001741732 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,600

F1 · balance_after: Includes 800 shares of common stock that was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on January 1, 2020 and April 1, 2020, if she is a director of the Company on those dates.

SEC source: 0001209191-19-058961 · doc4.xml · nonDerivative · entry 1

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,850

F1 · shares: Shares donated to charitable organization

F2 · balance_after: Includes 800 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 400 shares on each of January 1, 2020 and April 1, 2020, if he is a director of the Company on those dates.

SEC source: 0001209191-19-058409 · doc4.xml · nonDerivative · entry 1

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,350

F1 · balance_after: Includes 800 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 400 shares on each of January 1, 2020 and April 1, 2020, if he is a director of the Company on those dates.

SEC source: 0001209191-19-058051 · doc4.xml · nonDerivative · entry 2

MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,728

F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $113.00 to $114.11 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 17,398 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 2,500 shares on January 1, 2020; 1,790 shares on each of April 1, July 1 and October 1, 2020; 1,805 shares on January 1, 2021; 1,280 shares on each of April 1, July 1 and October 1, 2021; 1,288 on January 1, 2022; 648 on each of April 1, July 1 and October 1, 2022; and 651 on January 1, 2023.

SEC source: 0001209191-19-057902 · doc4.xml · nonDerivative · entry 1

REEVE GRAHAM D. · CIK 0001519948 · COO

10b5-1 filing: Not disclosed

Ownership: Indirect · Reeve Trust

Disclosed balance after: 3,839

F1 · balance_after: Shares are held in the Reeve Living Trust, which Mr. Reeve is a trustee and beneficiary.

SEC source: 0001209191-19-058051 · doc4.xml · nonDerivative · entry 1

MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,326

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $116.00 to $116.54 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 17,398 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 2,500 shares on January 1, 2020; 1,790 shares on each of April 1, July 1 and October 1, 2020; 1,805 shares on January 1, 2021; 1,280 shares on each of April 1, July 1 and October 1, 2021; 1,288 on January 1, 2022; 648 on each of April 1, July 1 and October 1, 2022; and 651 on January 1, 2023.

SEC source: 0001209191-19-057827 · doc4.xml · nonDerivative · entry 1

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,350

F1 · balance_after: Includes 800 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 400 shares on each of January 1, 2020 and April 1, 2020, if he is a director of the Company on those dates.

SEC source: 0001209191-19-056302 · doc4.xml · nonDerivative · entry 1

Chapman Harry S · CIK 0001500817 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,400

F1 · balance_after: Includes 800 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 400 shares on each of January 1, 2020 and April 1, 2020, if he is a director of the Company on those dates.

SEC source: 0001209191-19-046692 · doc4.xml · nonDerivative · entry 3

READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,058

F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $134.77 to $135.51 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 39,525 shares which restrictions lapse as to 4,984 shares on each of October 1, 2019 and January 1, 2020; 3,564 shares on each of April 1, July 1 and October 1, 2020; 3,578 shares on January 1, 2021; 2,543 shares on each of April 1, July 1 and October 1, 2021 and on January 1, 2022; 1,278 on each of April 1, July 1 and October 1, 2022; and 1,281 on January 1, 2023

SEC source: 0001209191-19-046692 · doc4.xml · nonDerivative · entry 2

READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,957

F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $135.00 to $135.31 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 39,525 shares which restrictions lapse as to 4,984 shares on each of October 1, 2019 and January 1, 2020; 3,564 shares on each of April 1, July 1 and October 1, 2020; 3,578 shares on January 1, 2021; 2,543 shares on each of April 1, July 1 and October 1, 2021 and on January 1, 2022; 1,278 on each of April 1, July 1 and October 1, 2022; and 1,281 on January 1, 2023

SEC source: 0001209191-19-046506 · doc4.xml · nonDerivative · entry 3

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,350

F1 · balance_after: Includes 1,200 shares of common stock granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares on each of October 1, 2019, January 1, 2020 and April 1, 2020, if he is a director of the Company on those dates.

SEC source: 0001209191-19-046692 · doc4.xml · nonDerivative · entry 1

READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,457

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $135.06 to $136.22 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 39,525 shares which restrictions lapse as to 4,984 shares on each of October 1, 2019 and January 1, 2020; 3,564 shares on each of April 1, July 1 and October 1, 2020; 3,578 shares on January 1, 2021; 2,543 shares on each of April 1, July 1 and October 1, 2021 and on January 1, 2022; 1,278 on each of April 1, July 1 and October 1, 2022; and 1,281 on January 1, 2023

SEC source: 0001209191-19-046506 · doc4.xml · nonDerivative · entry 2

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,350

F1 · balance_after: Includes 1,200 shares of common stock granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares on each of October 1, 2019, January 1, 2020 and April 1, 2020, if he is a director of the Company on those dates.

SEC source: 0001209191-19-046506 · doc4.xml · nonDerivative · entry 1

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,350

F1 · balance_after: Includes 1,200 shares of common stock granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares on each of October 1, 2019, January 1, 2020 and April 1, 2020, if he is a director of the Company on those dates.

SEC source: 0001209191-19-046056 · doc4.xml · nonDerivative · entry 1

McDowell Glenn · CIK 0001315304 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,898

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $134.50 to $134.86 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 19,898 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 2,500 shares on each of October 1, 2019 and January 1, 2020; 1,790 shares on each of April 1, July 1 and October 1, 2020; 1,805 shares on January 1, 2021; 1,280 shares on each of April 1, July 1 and October 1, 2021; 1,288 on January 1, 2022; 648 on each of April 1, July 1 and October 1, 2022; and 651 on January 1, 2023.

SEC source: 0001209191-19-045862 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,100

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $134.80 to $135.91 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 1,200 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on 400 shares on each of October 1, 2019, January 1, 2020 and April 1, 2020, if he is a director of the Company on those dates.

SEC source: 0001209191-19-046058 · doc4.xml · nonDerivative · entry 1

PULLINS JERALD L · CIK 0001242160 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,851

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $134.08 to $135.93 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 1,200 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on 400 shares on each of October 1, 2019, January 1, 2020 and April 1, 2020, if he is a director of the Company on those dates.

SEC source: 0001209191-19-045707 · doc4.xml · nonDerivative · entry 1

REEVE GRAHAM D. · CIK 0001519948 · COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,002

F1 · balance_after: Includes 13,808 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 1,121 shares on each of October 1, 2019, January 1, April 1, July1, October 1, 2020 and 2021; 1,124 shares on each of January 1, 2022; 645 shares on each of April 1, July 1 and October 1, 2022; 660 shares on January 1, 2023.

SEC source: 0001209191-19-045862 · doc4.xml · nonDerivative · entry 2

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,350

F3 · shares: Bona fide gift.

F2 · balance_after: Includes 1,200 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on 400 shares on each of October 1, 2019, January 1, 2020 and April 1, 2020, if he is a director of the Company on those dates.

SEC source: 0001209191-19-045468 · doc4.xml · nonDerivative · entry 2

MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,728

F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $130.07 to $131.01 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 19,898 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 2,500 shares on each of October 1, 2019 and January 1, 2020; 1,790 shares on each of April 1, July 1 and October 1, 2020; 1,805 shares on January 1, 2021; 1,280 shares on each of April 1, July 1 and October 1, 2021; 1,288 on January 1, 2022; 648 on each of April 1, July 1 and October 1, 2022; and 651 on January 1, 2023.

SEC source: 0001209191-19-045468 · doc4.xml · nonDerivative · entry 1

MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,028

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.02 to $133.45 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 19,898 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 2,500 shares on each of October 1, 2019 and January 1, 2020; 1,790 shares on each of April 1, July 1 and October 1, 2020; 1,805 shares on January 1, 2021; 1,280 shares on each of April 1, July 1 and October 1, 2021; 1,288 on January 1, 2022; 648 on each of April 1, July 1 and October 1, 2022; and 651 on January 1, 2023.

SEC source: 0001209191-19-032020 · doc4.xml · nonDerivative · entry 2

READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,058

F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $120.00 to $120.91 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 44,509 shares which restrictions lapse as to 4,984 shares on each of July 1, 2019, October 1, 2019 and January 1, 2020; 3,564 shares on each of April 1, July 1 and October 1, 2020; 3,578 shares on January 1, 2021; 2,543 shares on each of April 1, July 1 and October 1, 2021 and on January 1, 2022; 1,278 on each of April 1, July 1 and October 1, 2022; and 1,281 on January 1, 2023.

SEC source: 0001209191-19-031985 · doc4.xml · nonDerivative · entry 1

Gilmartin Kathleen A · CIK 0001741732 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,100

F1 · shares: The 1,600 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of July 1, 2019, October 1, 2019, January 1, 2020 and April 1, 2020, if she is a director of the Company on those dates.

F2 · balance_after: Includes the 1,600 shares discussed in Note 1.

SEC source: 0001209191-19-031987 · doc4.xml · nonDerivative · entry 1

KUNTZ EDWARD L · CIK 0001182168 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,600

F1 · shares: The 1,600 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of July 1, 2019, October 1, 2019, January 1, 2020 and April 1, 2020, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 1,600 shares discussed in Note 1.

SEC source: 0001209191-19-032020 · doc4.xml · nonDerivative · entry 1

READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,918

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $118.00 to $118.60 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 44,509 shares which restrictions lapse as to 4,984 shares on each of July 1, 2019, October 1, 2019 and January 1, 2020; 3,564 shares on each of April 1, July 1 and October 1, 2020; 3,578 shares on January 1, 2021; 2,543 shares on each of April 1, July 1 and October 1, 2021 and on January 1, 2022; 1,278 on each of April 1, July 1 and October 1, 2022; and 1,281 on January 1, 2023.

SEC source: 0001209191-19-032016 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,850

F1 · shares: The 1,600 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of July 1, 2019, October 1, 2019, January 1, 2020 and April 1, 2020, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 1,600 shares discussed in Note 1.

SEC source: 0001209191-19-032015 · doc4.xml · nonDerivative · entry 1

Swanson Regg E. · CIK 0001412473 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,600

F1 · shares: The 1,600 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of July 1, 2019, October 1, 2019, January 1, 2020 and April 1, 2020, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 1,600 shares discussed in Note 1.

SEC source: 0001209191-19-031988 · doc4.xml · nonDerivative · entry 1

PULLINS JERALD L · CIK 0001242160 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,851

F1 · shares: The 1,600 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of July 1, 2019, October 1, 2019, January 1, 2020 and April 1, 2020, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 1,600 shares discussed in Note 1.

SEC source: 0001209191-19-031986 · doc4.xml · nonDerivative · entry 1

Harris Bernard A Jr · CIK 0001337906 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,022

F1 · shares: The 1,600 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of July 1, 2019, October 1, 2019, January 1, 2020 and April 1, 2020, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 1,600 shares discussed in Note 1.

SEC source: 0001209191-19-031984 · doc4.xml · nonDerivative · entry 1

Chapman Harry S · CIK 0001500817 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,000

F1 · shares: The 1,600 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of July 1, 2019, October 1, 2019, January 1, 2020 and April 1, 2020, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 1,600 shares discussed in Note 1.

SEC source: 0001209191-19-031983 · doc4.xml · nonDerivative · entry 1

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,350

F1 · shares: The 1,600 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of July 1, 2019, October 1, 2019, January 1, 2020 and April 1, 2020, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 1,600 shares discussed in Note 1.

SEC source: 0001209191-19-028734 · doc4.xml · nonDerivative · entry 1

PULLINS JERALD L · CIK 0001242160 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,251

F1 · shares: Bona fide gift.

SEC source: 0001209191-19-028159 · doc4.xml · nonDerivative · entry 2

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,750

SEC source: 0001209191-19-028159 · doc4.xml · nonDerivative · entry 1

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,375

SEC source: 0001209191-19-027652 · doc4.xml · nonDerivative · entry 1

MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,228

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $115.70 to $117.30 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 22,398 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 2,500 shares on each of July 1, 2019, October 1, 2019 and January 1, 2020; 1,790 shares on each of April 1, July 1 and October 1, 2020; 1,805 shares on January 1, 2021; 1,280 shares on each of April 1, July 1 and October 1, 2021; 1,288 on January 1, 2022; 648 on each of April 1, July 1 and October 1, 2022; and 651 on January 1, 2023.

SEC source: 0001209191-19-027647 · doc4.xml · nonDerivative · entry 1

KUNTZ EDWARD L · CIK 0001182168 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $115.00 to $115.36 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-19-027645 · doc4.xml · nonDerivative · entry 2

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,000

SEC source: 0001209191-19-027645 · doc4.xml · nonDerivative · entry 1

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,125

SEC source: 0001209191-19-021902 · doc4.xml · nonDerivative · entry 1

Gilmartin Kathleen A · CIK 0001741732 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $105.10 to $105.23, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-19-019985 · doc4.xml · nonDerivative · entry 3

McDowell Glenn · CIK 0001315304 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,898

F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.00 to $107.37 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 24,898 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 2,500 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; 1,790 shares on each of April 1, July 1 and October 1, 2020; 1,805 shares on January 1, 2021; 1,280 shares on each of April 1, July 1 and October 1, 2021 and 1,288 shares on January 1, 2022; 648 on each of April 1, July 1 and October 1, 2022; and 651 on January 1, 2023.

SEC source: 0001209191-19-020520 · doc4.xml · nonDerivative · entry 1

Chapman Harry S · CIK 0001500817 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,400

F1 · balance_after: Includes 500 shares of restricted stock granted under the Company's equity plans which restrictions lapse on April 1, 2019.

SEC source: 0001209191-19-019985 · doc4.xml · nonDerivative · entry 2

McDowell Glenn · CIK 0001315304 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,297

F2 · balance_after: Includes 24,898 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 2,500 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; 1,790 shares on each of April 1, July 1 and October 1, 2020; 1,805 shares on January 1, 2021; 1,280 shares on each of April 1, July 1 and October 1, 2021 and 1,288 shares on January 1, 2022; 648 on each of April 1, July 1 and October 1, 2022; and 651 on January 1, 2023.

SEC source: 0001209191-19-019985 · doc4.xml · nonDerivative · entry 1

McDowell Glenn · CIK 0001315304 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,702

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $112.44 to $112.49 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 24,898 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 2,500 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; 1,790 shares on each of April 1, July 1 and October 1, 2020; 1,805 shares on January 1, 2021; 1,280 shares on each of April 1, July 1 and October 1, 2021 and 1,288 shares on January 1, 2022; 648 on each of April 1, July 1 and October 1, 2022; and 651 on January 1, 2023.

SEC source: 0001209191-19-019058 · doc4.xml · nonDerivative · entry 1

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,125

F1 · shares: Shares donated to charitable organization.

F2 · balance_after: Includes 500 shares of restricted stock granted under the Company's equity plans which restrictions lapse on April 1, 2019.

SEC source: 0001209191-19-018398 · doc4.xml · nonDerivative · entry 1

MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,728

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $105.00 to $107.04 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 24,898 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 2,500 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; 1,790 shares on each of April 1, July 1 and October 1, 2020; 1,805 shares on January 1, 2021; 1,280 shares on each of April 1, July 1 and October 1, 2021 and 1,288 shares on January 1, 2022; 648 on each of April 1, July 1 and October 1, 2022; and 651 on January 1, 2023.

SEC source: 0001209191-19-016720 · doc4.xml · nonDerivative · entry 1

REEVE GRAHAM D. · CIK 0001519948 · COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,954

F1 · shares: The 10,335 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 equal quarterly installment with the 645 shares on April 1, 2019 and thereafter with 645 shares on April 1, July 1, October 1 and January 1 of each year with the final 660 shares lapsing on January 1, 2023.

F2 · balance_after: Includes 16,050 shares, inclusive of the 10,335 shares in footnote 1, of restricted stock granted under the Company's equity plans. Restrictions lapse as to 1,121 shares on each of April 1, 2019, July 1, 2019, October 1, 2019, January 1, 2020, April 1, 2020, July 1, 2020, October 1, 2020, January 1, 2021, April 1, 2021, July 1, 2021 and October 1, 2021; and 1,124 shares on January 1, 2022; 645 on each of April 1, July 1 and October 1, 2022; and 660 on January 1, 2023.

SEC source: 0001209191-19-016719 · doc4.xml · nonDerivative · entry 1

READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,918

F1 · shares: The 20,451 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 equal quarterly installment with the 1,278 shares on April 1, 2019 and thereafter with 1,278 on April 1, July 1, October 1 and January 1 of each year with the final 1,281 shares lapsing on January 1, 2023.

F2 · balance_after: Includes 49,493 shares, inclusive of the 20,451 shares in footnote 1, of restricted stock granted under the Company's equity plans. Restrictions lapse as to 4,984 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; 3,564 shares on each of April 1, July 1 and October 1, 2020; 3,578 shares on January 1, 2021; 2,543 shares on each of April 1, July 1 and October 1, 2021 and on January 1, 2022; 1,278 on each of April 1, July 1 and October 1, 2022; and 1,281 on January 1, 2023.

SEC source: 0001209191-19-016715 · doc4.xml · nonDerivative · entry 1

MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,878

F1 · shares: The 10,371 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 equal quarterly installment with the 648 shares on April 1, 2019 and thereafter with 648 shares on April 1, July 1, October 1 and January 1 of each year with the final 651 shares lapsing on January 1, 2023.

F2 · balance_after: Includes 24,898 shares, inclusive of the 10,371 shares in footnote 1, of restricted stock granted under the Company's equity plans. Restrictions lapse as to 2,500 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; 1,790 shares on each of April 1, July 1 and October 1, 2020; 1,805 shares on January 1, 2021; 1,280 shares on each of April 1, July 1 and October 1, 2021; 1288 shares on January 1, 2022; 648 on each of April 1, July 1 and October 1, 2022; and 651 on January 1, 2023.

SEC source: 0001209191-19-016713 · doc4.xml · nonDerivative · entry 1

McDowell Glenn · CIK 0001315304 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,102

F1 · shares: The 10,371 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 equal quarterly installment with the 648 shares on April 1, 2019 and thereafter with 648 shares on April 1, July 1, October 1 and January 1 of each year with the final 651 shares lapsing on January 1, 2023.

F2 · balance_after: Includes 24,898 shares, inclusive of the 10,371 shares in footnote 1, of restricted stock granted under the Company's equity plans. Restrictions lapse as to 2,500 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; 1,790 shares on each of April 1, July 1 and October 1, 2020; 1,805 shares on January 1, 2021; 1,280 shares on each of April 1, July 1 and October 1, 2021; 1288 shares on January 1, 2022; 648 on each of April 1, July 1 and October 1, 2022; and 651 on January 1, 2023.

SEC source: 0001209191-18-064199 · doc4.xml · nonDerivative · entry 2

Swanson Regg E. · CIK 0001412473 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust

Disclosed balance after: 2,596

F1 · balance_after: Regg E Swanson Revocable Trust is the owner and Beneficiary and Trustee